Income Statement
IMMIX BIOPHARMA, INC.
IMMX
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - |
|
Operating Expenses
|
29.96 | 22.67 | 16.14 | 8.22 | 1.35 |
|
Research & Development
|
16.26 | 11.29 | 8.74 | 4.20 | 0.13 |
|
Selling, General & Administrative
|
13.70 | 11.38 | 7.41 | 4.02 | 1.23 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-29.96 | -22.67 | -16.14 | -8.22 | -1.35 |
|
Non-Operating Income
|
0.56 | 1.02 | 0.57 | 0.00 | -23.03 |
|
Interest Income
|
0.56 | 1.02 | 0.57 | - | - |
|
Interest Expense
|
- | - | - | 0.00 | 0.18 |
|
Other Non-Op Income / Expense
|
- | - | - | - | - |
|
Income Before Tax
|
-29.40 | -21.66 | -15.57 | -8.22 | -24.38 |
|
Income Tax Expense
|
0.04 | -0.04 | -0.14 | 0.01 | 0.01 |
|
Non-Controlling Interest
|
- | -0.08 | -0.17 | - | - |
|
Net Income
|
-29.44 | -21.61 | -15.43 | -8.23 | -24.38 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-29.96 | -22.67 | -16.14 | -8.22 | -1.35 |
|
Earnings Per Share (Basic)
|
-0.89 | -0.76 | -0.89 | -0.59 | - |
|
Diluted EPS
|
-0.89 | -0.76 | -0.89 | - | - |
|
Weighted Average Shares
|
32.97 | 28.29 | 17.34 | 13.89 | - |
|
Diluted Weighted Avg Shares
|
32.97 | 28.29 | 17.34 | - | - |
|
Comprehensive Income
|
- | -21.75 | -15.38 | -8.27 | -24.39 |